文献速递前列腺癌

双参数与多参数前列腺磁共振成像在初治患者前列腺癌检测中的诊断试验准确性系统评价与荟萃分析

Biparametric vs multiparametric prostate magnetic resonance imaging for the detection of prostate cancer in treatment-naïve patients: a diagnostic test accuracy systematic review and meta-analysis.
PubMed 文献 · BJU Int · 2019-04-25

该系统评价与荟萃分析纳入31项研究共9480例患者,比较双参数MRI(bpMRI)与多参数MRI(mpMRI)在初治疑似前列腺癌患者中的诊断准确性。汇总分析显示两者敏感性和特异性均无显著差异,汇总受试者工作特征曲线下面积相近。研究异质性大,需谨慎解读;作者认为经专门验证研究重复后,bpMRI或可作为更快、更便宜、无钆对比剂的替代方案。

要点

  • 31项研究共9480例患者(4296例前列腺癌)纳入荟萃分析。
  • mpMRI与bpMRI的敏感性、特异性均无显著差异。
  • 研究异质性大,需谨慎解读;bpMRI或可成为mpMRI的替代方案。

核心结论

  • 在初治患者中,mpMRI与bpMRI诊断前列腺癌的准确性无显著差异。
  • 研究异质性要求对结果谨慎解读。
  • 若专门验证研究能重复本研究发现,bpMRI或可作为更快、更便宜、无钆对比剂的mpMRI替代方案。

研究设计与样本

  • 诊断试验准确性系统评价与荟萃分析,检索MEDLINE和EMBASE中2012年1月1日之后发表的相关研究。
  • 纳入标准为疑似前列腺癌患者、以bpMRI和/或mpMRI为索引试验、以组织病理学为参考标准、报告诊断试验准确性结局指标。
  • 最终纳入31项研究共9480例患者(4296例前列腺癌);其中25项研究报告mpMRI(7000例患者,2954例前列腺癌),12项研究报告bpMRI诊断试验准确性(2716例患者,1477例前列腺癌)。
  • 使用QUADAS-2工具评估偏倚风险,采用双变量随机效应荟萃分析汇总诊断试验准确性指标,并进行亚组分析评估异质性。

主要发现

  • 敏感性:mpMRI为86%(95%CI 81-90),bpMRI为90%(95%CI 83-94),两者无显著差异。
  • 特异性:mpMRI为73%(95%CI 64-81),bpMRI为70%(95%CI 42-83),两者无显著差异。
  • 汇总受试者工作特征曲线:mpMRI为0.87,bpMRI为0.90,两者相近。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究异质性大,需谨慎解读结果。
  • 研究结果需在专门验证研究中重复后方可考虑bpMRI作为替代方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To perform a diagnostic test accuracy (DTA) systematic review and meta-analysis comparing multiparametric (diffusion-weighted imaging [DWI], T2-weighted imaging [T2WI], and dynamic contrast-enhanced [DCE] imaging) magnetic resonance imaging (mpMRI) and biparametric (DWI and T2WI) MRI (bpMRI) in detecting prostate cancer in treatment-naïve patients. METHODS: The Medical Literature Analysis and Retrieval System Online (MEDLINE) and Excerpta Medica dataBASE (EMBASE) were searched to identify relevant studies published after 1 January 2012. Articles underwent title, abstract, and full-text screening. Inclusion criteria consisted of patients with suspected prostate cancer, bpMRI and/or mpMRI as the index test(s), histopathology as the reference standard, and a DTA outcome measure. Methodological and DTA data were extracted. Risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 tool. DTA metrics were pooled using bivariate random-effects meta-analysis. Subgroup analysis was conducted to assess for heterogeneity. RESULTS: From an initial 3502 studies, 31 studies reporting on 9480 patients (4296 with prostate cancer) met the inclusion criteria for the meta-analysis; 25 studies reported on mpMRI (7000 patients, 2954 with prostate cancer) and 12 studies reported on bpMRI DTA (2716 patients, 1477 with prostate cancer). Pooled summary statistics demonstrated no significant difference for sensitivity (mpMRI: 86%, 95% confidence interval [CI] 81-90; bpMRI: 90%, 95% CI 83-94) or specificity (mpMRI: 73%, 95% CI 64-81; bpMRI: 70%, 95% CI 42-83). The summary receiver operating characteristic curves were comparable for mpMRI (0.87) and bpMRI (0.90). CONCLUSIONS: No significant difference in DTA was found between mpMRI and bpMRI in diagnosing prostate cancer in treatment-naïve patients. Study heterogeneity warrants cautious interpretation of the results. With replication of our findings in dedicated validation studies, bpMRI may serve as a faster, cheaper, gadolinium-free alternative to mpMRI.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Alabousi M, Salameh JP, Gusenbauer K, et al. Biparametric vs multiparametric prostate magnetic resonance imaging for the detection of prostate cancer in treatment-naïve patients: a diagnostic test accuracy systematic review and meta-analysis. BJU Int. 2019. PMID: 30929292. doi:10.1111/bju.14759

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。